CNR2 and allergic disease: Because an orally bioavailable CB2 antagonist was recently used in a first phase 1/phase 2 study in humans (NCT05525455), our data prove that antagonistic targeting of CB2 receptor may have additional potential for the treatment of allergic diseases characterized by eosinophil infiltration.